Sensodetect embarks on strategic business mission to China and the Middle East: showcasing next-generation AI diagnostics and future ABR+ERP (EEG) technology roadmap to large investors

Sensodetect AB, a pioneer in neurodiagnostic technology, today announced that its leadership team is undertaking an international business mission to China and the Middle East. The trip will highlight not only the company’s commitment to market expansion but also its next-generation hardware and AI-driven diagnostic platform, alongside a long-term roadmap integrating Auditory Brainstem Response (ABR) with Event-Related Potentials (ERP) via EEG.

A central focus of the trip will be advancing the company’s ongoing regulatory approval process with the National Medical Products Administration (NMPA) in China. Meetings with regulators, clinical partners, and key stakeholders are expected to stimulate progress toward approval and align on the final steps required for market entry. Sensodetect views NMPA approval as a critical milestone for expanding access to its breakthrough neurodiagnostic tools in the world’s second-largest healthcare market.

In parallel, the company will engage in joint venture discussions with leading Chinese investment and healthcare groups. These talks aim to give a large capital infusion and establish a long-term strategic collaboration that supports not only commercialization in China but also future research, development, and manufacturing partnerships in the region.

During the mission, Sensodetect will showcase its next version of its hardware in combination with its newly developed AI solution. This integrated approach is designed to enhance diagnostic accuracy, speed, and clinical usability.

Looking ahead, Sensodetect is also laying the foundation for it's next generation solution that combines ABR with ERP (EEG). This innovation represents a major step toward a more comprehensive neurodiagnostic platform, providing clinicians with deeper, objective insights into brain function.

Following China, the Sensodetect team will visit the Middle East for business discussions with healthcare providers, distributors, and policymakers. The region presents strong demand for innovative diagnostic solutions, and the company sees significant opportunities to contribute to improved mental healthcare outcomes.

The international mission will also serve as a platform for advancing discussions around product launch timelines. Sensodetect plans to align with regional partners on distribution strategies, market readiness, and clinical adoption to ensure a successful roll-out in both China and the Middle East.

For more information or partnership inquiries, please contact:

PA Hedin, CEO Sensodetect AB

+46 (0)46 15 79 04
pa.hedin@sensodetect.com

SensoDetect AB is a Med Tech AI company listed on the Spotlight Stock Market. The company was founded in Lund in 2005, based on more than 30 years of research in clinical psychoacoustics at the Department of Neuroscience at Lund University. Initially, the focus was on patients with schizophrenia, as auditory hallucinations are a common symptom of the disease. However, today, the company offers a variety of other services within the product areas of screening, diagnostics, medication, and health. The products are used in both private and public healthcare and schools, as a screening and complement to other observations in ADHD, schizophrenia, and autism assessments, in measuring the effects of medication, and in hearing screening. SensoDetect's unique and globally patented technology reduces the economic impact on healthcare and society while providing patients and their families with faster and more reliable results.

More info at https://www.sensodetect.com/